{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:50:26Z","timestamp":1789498226239,"version":"build-2803163510"},"reference-count":31,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005888","name":"Uniwersytet Medyczny w Lodzi","doi-asserted-by":"publisher","award":["503\/1-093-01\/503-11-004-18"],"award-info":[{"award-number":["503\/1-093-01\/503-11-004-18"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The purine nucleoside analogues cladribine and pentostatin are highly-active first-line therapeutic treatments for hairy cell leukemia (HCL), resulting in complete response rates of 80% to 90%. However, HCL patients continue to relapse, and sooner or later, most require subsequent lines of treatment. This report presents the cases of four relapsed patients with classic HCL who were treated with vemurafenib (mostly at the low dose of 240 mg twice daily for 16 weeks) combined with rituximab after the failure of several lines of therapy including cladribine with or without rituximab and moxetumomab pasudotox. Two patients achieved minimal residual disease negative complete response after combined treatment with vemurafenib and rituximab, with a hematologic response ongoing after 38 months from the end of treatment in one patient and a relapse of cytopenias occurring after 13 months in the other patient. A third patient normalized her blood counts and this hematologic response, which was not evaluated in the bone marrow at the end of treatment, was lost after 18 months. The last patient died due to infection and multi-organ failure, too early to verify response to vemurafenib. Two patients who had relapsed after vemurafenib and rituximab derived meaningful clinical benefit from retreatment with the same agents, but eventually relapsed again and started indefinite therapy with dabrafenib and trametinib leading to normalization of the blood counts (despite heavy bone marrow infiltration in the only patient so far evaluable in that regard). The outcomes of these cases indicate that novel targeted agents and, in particular, vemurafenib, combined with rituximab, improve the prognosis of HCL patients, even those heavily pretreated with PNAs and moxetumomab pasudotox.<\/jats:p>","DOI":"10.3390\/jcm10132800","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T11:07:40Z","timestamp":1624619260000},"page":"2800","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-6357","authenticated-orcid":false,"given":"Tadeusz","family":"Robak","sequence":"first","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, 93-510 Lodz, Poland"},{"name":"Copernicus Memorial Hospital, 93-510 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Janus","sequence":"additional","affiliation":[{"name":"Copernicus Memorial Hospital, 93-510 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Jamroziak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Tiacci","sequence":"additional","affiliation":[{"name":"Institute of Hematology, University and Hospital of Perugia, 06132 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Kreitman","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, Clinical Immunotherapy Section, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","article-title":"Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia","volume":"129","author":"Grever","year":"2017","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"v100","DOI":"10.1093\/annonc\/mdv200","article-title":"ESMO Guidelines Committee. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Robak","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA A Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_6","first-page":"2981","article-title":"Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin","volume":"96","author":"Flinn","year":"2000","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1200\/JCO.2003.05.093","article-title":"Extended Follow-Up of Patients With Hairy Cell Leukemia After Treatment With Cladribine","volume":"21","author":"Goodman","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1002\/cncr.25243","article-title":"Hairy cell leukemia: Evaluation of the long-term outcome in 121 patients","volume":"116","author":"Zinzani","year":"2010","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2141.2009.07668.x","article-title":"Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis","volume":"145","author":"Else","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1200\/JCO.2011.38.1756","article-title":"Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients with Hairy Cell Leukemia","volume":"30","author":"Kreitman","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"2018","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-01004-y","article-title":"Moxetumomab pasudotox in heavily pre-treated patients with relapsed\/refractory hairy cell leukemia (HCL): Long-term follow-up from the pivotal trial","volume":"14","author":"Kreitman","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia","volume":"373","author":"Tiacci","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/blood-2015-11-680074","article-title":"BRAF inhibition in hairy cell leukemia with low-dose vemurafenib","volume":"127","author":"Dietrich","year":"2016","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1038\/s41375-019-0646-y","article-title":"BRAF inhibitor treatment in classic hairy cell leukemia: A long-term follow-up study of patients treated outside clinical trials","volume":"34","author":"Liebers","year":"2019","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2018-99-113135","article-title":"Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent\/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL)","volume":"132","author":"Kreitman","year":"2018","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa2031298","article-title":"Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia","volume":"384","author":"Tiacci","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1182\/blood-2011-08-371179","article-title":"Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation","volume":"119","author":"Tiacci","year":"2012","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.17201","article-title":"The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant","volume":"193","author":"Troussard","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Assanto, G.M., Riemma, C., Malaspina, F., Perrone, S., De Luca, M.L., Pucciarini, A., Annechini, G., D\u2019Elia, G.M., Martelli, M., and Fo\u00e0, R. (2021). The current role of interferon in hairy cell leukaemia: Clinical and molecular aspects. Br. J. Haematol.","DOI":"10.1111\/bjh.17440"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/10428194.2011.573033","article-title":"Historical treatments of in hairy cell leukemia, splenectomy and interferon: Past and current uses","volume":"52","author":"Habermann","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2017-09-803072","article-title":"Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: Phase 1 results and long-term follow-up","volume":"131","author":"Kreitman","year":"2018","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/14712598.2019.1614558","article-title":"Moxetumomab pasudotox for the treatment of hairy cell leukemia","volume":"19","author":"Janus","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Tiacci, E., De Carolis, L., Simonetti, E., Merluzzi, M., Bennati, A., Perriello, V.M., Pucciarini, A., Santi, A., Venanzi, A., and Pettirossi, V. (2021). Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: A pilot phase-2 clinical trial. Leukemia.","DOI":"10.1038\/s41375-021-01210-8"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Rogers, K.A., Andritsos, L.A., Wei, L., McLaughlin, E., Ruppert, A.S., Anghelina, M., Blachly, J.S., Call, T.G., Chihara, D., and Dauki, A.M. (2021). Phase 2 Study of Ibrutinib in Classic and Variant Hairy Cell Leukemia. Blood.","DOI":"10.1182\/blood.2020009688"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1182\/bloodadvances.2018027466","article-title":"Classic hairy cell leukemia complicated by pancytopenia and severe infection: A report of 3 cases treated with vemurafenib","volume":"3","author":"Shenoi","year":"2019","journal-title":"Blood Adv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"E180","DOI":"10.1002\/ajh.25474","article-title":"Low-dose vemurafenib in hairy cell leukemia patients with active infection","volume":"94","author":"Bohn","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"106571","DOI":"10.1016\/j.leukres.2021.106571","article-title":"Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab","volume":"104","author":"Robak","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"106522","DOI":"10.1016\/j.leukres.2021.106522","article-title":"Targeted therapy for treatment of patients with classical hairy cell leukemia","volume":"102","author":"Moore","year":"2021","journal-title":"Leuk. Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Smirnova, S.Y., Al-Radi, L.S., Moiseeva, T.N., Gemdzhian, E.G., Yakutik, I.A., Julhakyan, H.L., Novikov, V.A., Galstyan, G.M., and Sudarikov, A.B. (2021). Inhibitor of BRAFV600E Mutation as a Treatment Option for Hairy Cell Leukemia With Deep Neutropenia and Infectious Complications. Clin. Lymphoma Myeloma Leuk.","DOI":"10.1016\/j.clml.2021.02.005"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1158\/1078-0432.CCR-13-1848","article-title":"Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia","volume":"19","author":"Burotto","year":"2013","journal-title":"Clin. Cancer Res."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/13\/2800\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:24:05Z","timestamp":1760163845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/13\/2800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":31,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["jcm10132800"],"URL":"https:\/\/doi.org\/10.3390\/jcm10132800","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202106.0092.v1","asserted-by":"object"}]},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]}}}